Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)

To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.

本研究旨在探究纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）用于既往未经治疗的晚期或转移性肾细胞癌（Renal Cell Cancer）受试者的安全性。